Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the FirmBusiness Wire • Tuesday
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead DrugZacks Investment Research • 09/11/24
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell LymphomaGlobeNewsWire • 09/10/24
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 09/03/24
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial ResultsGlobeNewsWire • 08/06/24
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)GlobeNewsWire • 08/01/24
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024GlobeNewsWire • 07/31/24
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/06/24
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024GlobeNewsWire • 05/02/24
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingGlobeNewsWire • 05/02/24
Here's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 WeeksZacks Investment Research • 04/17/24
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisGlobeNewsWire • 04/09/24
Down -18.35% in 4 Weeks, Here's Why Corvus (CRVS) Looks Ripe for a TurnaroundZacks Investment Research • 04/01/24
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/19/24
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024GlobeNewsWire • 03/13/24
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory DiseasesGlobeNewsWire • 02/12/24